Compass Therapeutics Investor Presentation Deck

Corporate Highlights We are a clinical stage biotech company developing antibody therapeutics for cancer LEAD ASSETS CORE SCIENCE RESOURCES COMPASS THERAPEUTICS CTX-009: DLL4 x VEGF-A bispecific antibody CTX-471: CD137 agonist antibody CTX-8371: PD-1 x PD-L1 bispecific antibody Stitch MabsTM platform designed to identify synergistic bispecific antibodies Common Light Chain technology enables multi-specificity and manufacturability Pre-clinical discovery 8 Cash runway into 2026 (Dec 2022: $187M in cash & marketable securities, $80M PIPE Nov 2022) Funded by leading life-science investors -25 FTES based in Boston, MA with experienced leadership team 32

View entire presentation